Edition:
India

EyePoint Pharmaceuticals Inc (EYPT.OQ)

EYPT.OQ on NASDAQ Stock Exchange Global Market

1.90USD
1:30am IST
Change (% chg)

$0.03 (+1.60%)
Prev Close
$1.87
Open
$1.89
Day's High
$1.92
Day's Low
$1.83
Volume
93,899
Avg. Vol
117,406
52-wk High
$3.94
52-wk Low
$1.20

Latest Key Developments (Source: Significant Developments)

Eyepoint Pharmaceuticals Reports Second Quarter 2019 Financial Results
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - EyePoint Pharmaceuticals Inc ::EYEPOINT PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS.Q2 LOSS PER SHARE $0.11.Q2 REVENUE $7.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $6.7 MILLION.EXISTING CASH & CASH EQUIVALENTS, CASH INFLOWS FROM EXPECTED DRUG SALES SUFFICIENT TO FUND OPERATING PLAN INTO 2020.  Full Article

Eyepoint Pharmaceuticals Says Public Offering Of 10.5 Mln Common Shares Priced At $1.90 Per Share
Thursday, 28 Mar 2019 

March 28 (Reuters) - EyePoint Pharmaceuticals Inc ::EYEPOINT PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 10.5 MILLION COMMON SHARES PRICED AT $1.90PER SHARE.  Full Article

EyePoint Pharmaceuticals Q1 Loss Per Share $0.44
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - EyePoint Pharmaceuticals Inc ::EYEPOINT PHARMACEUTICALS REPORTS FISCAL FIRST QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL AND OPERATIONAL DEVELOPMENTS.Q1 LOSS PER SHARE $0.44.Q1 REVENUE $486,000 VERSUS $385,000.Q1 REVENUE VIEW $708,000 -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.  Full Article

EyePoint Pharmaceuticals And Ocumension Therapeutics Sign Exclusive License Agreement
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - EyePoint Pharmaceuticals Inc ::EYEPOINT PHARMACEUTICALS AND OCUMENSION THERAPEUTICS SIGN EXCLUSIVE LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS IN THE GREATER CHINA REGION.EYEPOINT PHARMACEUTICALS INC - WILL RECEIVE A ONE-TIME UPFRONT PAYMENT OF $1.75 MILLION FROM OCUMENSION.EYEPOINT PHARMACEUTICALS INC - ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $10.0 MILLION IF CERTAIN FUTURE SALES AND MILESTONES ARE ACHIEVED BY OCUMENSION.EYEPOINT PHARMACEUTICALS -OCUMENSION TO RECEIVE EXCLUSIVE RIGHTS TO DEVELOP,COMMERCIALIZE PRODUCT IN AGREED TO TERRITORIES, AT ITS OWN COST, EXPENSE.  Full Article

pSivida Corp Announces Transformative Acquisition Of Icon Bioscience
Thursday, 29 Mar 2018 

March 28 (Reuters) - pSivida Corp ::PSIVIDA CORP ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS – COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS INC.PSIVIDA CORP - SWK HOLDINGS WILL PROVIDE UP TO $20 MILLION IN DEBT FINANCING.PSIVIDA CORP - DEAL FOR APPROXIMATELY $60.5 MILLION.PSIVIDA CORP - PSIVIDA CORP. WILL REBRAND AND CHANGE ITS NAME TO EYEPOINT PHARMACEUTICALS INC..PSIVIDA CORP - ENTERED INTO A FINANCIAL AGREEMENT WITH EW HEALTHCARE PARTNERS.PSIVIDA CORP - EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE EQUITY INVESTMENTS IN PSIVIDA.PSIVIDA CORP - WILL USE FUNDS TO FINANCE ICON ACQUISITION AND PREPARE FOR COMMERCIAL LAUNCHES OF DEXYCU.PSIVIDA CORP - IF APPROVED, PSIVIDA EXPECTS TO LAUNCH DURASERT IN U.S. IN FIRST HALF OF 2019.PSIVIDA CORP - PSIVIDA PLANS TO LAUNCH DEXYCU IN U.S. IN FIRST HALF OF 2019.PSIVIDA CORP - EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE AN EQUITY INVESTMENT IN PSIVIDA FOR UP TO ABOUT $60.5 MILLION.  Full Article

pSivida Says FDA Accepts NDA For Posterior Segment Uveitis Treatment
Monday, 19 Mar 2018 

March 19 (Reuters) - pSivida Corp ::PSIVIDA ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION (NDA) FOR DURASERT THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS.APPLICATION WILL HAVE PDUFA DATE OF NOVEMBER 5.  Full Article

Psivida Corp Reports Q2 Loss Per Share $0.13
Thursday, 8 Feb 2018 

Feb 7 (Reuters) - Psivida Corp ::REPORTS SECOND QUARTER FY2018 RESULTS; CONTINUES TO ACHIEVE MILESTONES AND TIMELINES.Q2 LOSS PER SHARE $0.13.  Full Article

pSivida Submits New Drug Application For Durasert Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA
Monday, 8 Jan 2018 

Jan 8 (Reuters) - pSivida Corp ::PSIVIDA SUBMITS NEW DRUG APPLICATION (NDA) FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS TO THE U.S. FDA.PSIVIDA CORP - ‍SUBMITTED NDA TO U.S. FDA FOR DURASERT THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS​.  Full Article

Psivida Granted Waiver By The FDA For New Drug Application Filing Fee
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Psivida Corp ::PSIVIDA GRANTED WAIVER BY THE FDA FOR NEW DRUG APPLICATION FILING FEE.PSIVIDA CORP - ON TRACK TO FILE DURASERT NDA IN EARLY JANUARY.PSIVIDA - FDA GRANTED BUSINESS WAIVER OF PDUFA FEE OF ABOUT $2.4 MILLION FOR NDA FOR CO'S DURASERT 3 YEAR MICROINSERT FOR POSTERIOR SEGMENT UVEITIS.  Full Article

pSivida reports Q1 loss per share of $0.15
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - pSivida Corp ::Q1 loss per share $0.15.Q1 revenue $385,000 versus $277,000.Q1 revenue view $640,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article